^
Association details:
| Biomarker: | TMB-H + PD-L1 expression |
|---|---|
| Cancer: | Small Cell Lung Cancer |
| Drug: | Tecentriq (atezolizumab) (PD-L1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Potential immune escape mechanisms underlying the distinct clinical outcome of immune checkpoint blockades in small cell lung cancer
Published date:
06/28/2019
Excerpt:
Only atezolizumab in combination with chemotherapy improved overall survival over chemotherapy alone… selecting tumor mutation burden in combination with PD-L1 expression as biomarkers could be promising strategies to improve the clinical efficacy of immunotherapy for SCLC... SCLC, with a high TMB similar to that of NSCLC, is theoretically likely to respond to immunotherapy.
DOI:
10.1186/s13045-019-0753-2
